191 related articles for article (PubMed ID: 32905759)
1. Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion.
Shibata S; Ajiro M; Hagiwara M
Cell Chem Biol; 2020 Dec; 27(12):1472-1482.e6. PubMed ID: 32905759
[TBL] [Abstract][Full Text] [Related]
2. Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation.
Arora K; Yarlagadda S; Zhang W; Moon C; Bouquet E; Srinivasan S; Li C; Stokes DC; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2016 Aug; 311(2):L364-74. PubMed ID: 27261451
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells.
Michaels WE; Bridges RJ; Hastings ML
Nucleic Acids Res; 2020 Jul; 48(13):7454-7467. PubMed ID: 32520327
[TBL] [Abstract][Full Text] [Related]
4. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
[TBL] [Abstract][Full Text] [Related]
5. Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
Igreja S; Clarke LA; Botelho HM; Marques L; Amaral MD
Hum Mutat; 2016 Feb; 37(2):209-15. PubMed ID: 26553470
[TBL] [Abstract][Full Text] [Related]
6. Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element.
Pagani F; Buratti E; Stuani C; Romano M; Zuccato E; Niksic M; Giglio L; Faraguna D; Baralle FE
J Biol Chem; 2000 Jul; 275(28):21041-7. PubMed ID: 10766763
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
8. Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA.
Sanz DJ; Hollywood JA; Scallan MF; Harrison PT
PLoS One; 2017; 12(9):e0184009. PubMed ID: 28863137
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Faà V; Incani F; Meloni A; Corda D; Masala M; Baffico AM; Seia M; Cao A; Rosatelli MC
J Biol Chem; 2009 Oct; 284(44):30024-31. PubMed ID: 19759008
[TBL] [Abstract][Full Text] [Related]
10. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
11. Rescue of common exon-skipping mutations in cystic fibrosis with modified U1 snRNAs.
Donegà S; Rogalska ME; Pianigiani G; Igreja S; Amaral MD; Pagani F
Hum Mutat; 2020 Dec; 41(12):2143-2154. PubMed ID: 32935393
[TBL] [Abstract][Full Text] [Related]
12. Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis.
Michaels WE; Pena-Rasgado C; Kotaria R; Bridges RJ; Hastings ML
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017302
[No Abstract] [Full Text] [Related]
13. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene.
Aznarez I; Chan EM; Zielenski J; Blencowe BJ; Tsui LC
Hum Mol Genet; 2003 Aug; 12(16):2031-40. PubMed ID: 12913074
[TBL] [Abstract][Full Text] [Related]
14. Multi-physiopathological consequences of the c.1392G>T CFTR mutation revealed by clinical and cellular investigations.
Farhat R; El-Seedy A; El-Moussaoui K; Pasquet MC; Adolphe C; Bieth E; Languepin J; Sermet-Gaudelus I; Kitzis A; Ladevèze V
Biochem Cell Biol; 2015 Feb; 93(1):28-37. PubMed ID: 25403292
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
17. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations.
Nissim-Rafinia M; Chiba-Falek O; Sharon G; Boss A; Kerem B
Hum Mol Genet; 2000 Jul; 9(12):1771-8. PubMed ID: 10915765
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous spectrum of mutations in CFTR gene from Indian patients with congenital absence of the vas deferens and their association with cystic fibrosis genetic modifiers.
Sharma H; Mavuduru RS; Singh SK; Prasad R
Mol Hum Reprod; 2014 Sep; 20(9):827-35. PubMed ID: 24958810
[TBL] [Abstract][Full Text] [Related]
19. A novel exon in the cystic fibrosis transmembrane conductance regulator gene activated by the nonsense mutation E92X in airway epithelial cells of patients with cystic fibrosis.
Will K; Dörk T; Stuhrmann M; Meitinger T; Bertele-Harms R; Tümmler B; Schmidtke J
J Clin Invest; 1994 Apr; 93(4):1852-9. PubMed ID: 7512993
[TBL] [Abstract][Full Text] [Related]
20. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
